Table 1. Candidate therapeutic targets and biomarkers of response to irinotecan derived from an improved understanding of topoisomerase I activity and subsequent DNA repair mechanisms.
|
Potential clinical utility
|
|||
|---|---|---|---|
| Molecule | Therapeutic target | Biomarker of response | Reference |
| Top I | Mechanism of action of Irinotecan | Yes | Braun et al, 2008 |
| TDP1 | Yes | Proposed | El-Khamisy et al, 2005, 2007 |
| PARP | Yes | ? | Smith et al, 2005; Zhang et al, 2011 |
| Aprataxin | ? | Yes | Dopeso et al, 2010 |
| Mismatch repair | ? | Yes | Bertagnolli et al, 2009 |
Abbreviations: PARP=poly(ADP-ribose) polymerase; TDP1=tyrosyl DNA phosphodiesterase 1; Top I=type I topoisomerases.